Expression of pathogenic SCN9A mutations in the zebrafish: A model to study small-fiber neuropathy.


Journal

Experimental neurology
ISSN: 1090-2430
Titre abrégé: Exp Neurol
Pays: United States
ID NLM: 0370712

Informations de publication

Date de publication:
01 2019
Historique:
received: 18 04 2018
revised: 21 09 2018
accepted: 10 10 2018
pubmed: 15 10 2018
medline: 11 4 2019
entrez: 15 10 2018
Statut: ppublish

Résumé

Small-fiber neuropathy (SFN) patients experience a spectrum of sensory abnormalities, including attenuated responses to non-noxious temperatures in combination with a decreased density of the small-nerve fibers. Gain-of-function mutations in the voltage-gated sodium channels SCN9A, SCN10A and SCN11A have been identified as an underlying genetic cause in a subpopulation of patients with SFN. Based on clinical-diagnostic tests for SFN, we have set up a panel of two read-outs reflecting SFN in zebrafish, being nerve density and behavioral responses. Nerve density was studied using a transgenic line in which the sensory neurons are GFP-labelled. For the behavioral experiments, a temperature-controlled water compartment was developed. This device allowed quantification of the behavioral response to temperature changes. By using these read-outs we demonstrated that zebrafish embryos transiently overexpressing the pathogenic human SCN9A p.(I228M) or p.(G856D) mutations both have a significantly decreased density of the small-nerve fibers. Additionally, larvae overexpressing the p.(I228M) mutation displayed a significant increase in activity induced by temperature change. As these features closely resemble the clinical hallmarks of SFN, our data suggest that transient overexpression of mutant human mRNA provides a model for SFN in zebrafish. This disease model may provide a basis for testing the pathogenicity of novel genetic variants identified in SFN patients. Furthermore, this model could be used for studying SFN pathophysiology in an in vivo model and for testing therapeutic interventions.

Identifiants

pubmed: 30316835
pii: S0014-4886(18)30572-7
doi: 10.1016/j.expneurol.2018.10.008
pii:
doi:

Substances chimiques

NAV1.7 Voltage-Gated Sodium Channel 0
SCN9A protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-264

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Ivo Eijkenboom (I)

Department of Genetics and Cell Biology, Clinical Genomics Unit, Maastricht University, Maastricht, the Netherlands; MHeNs school for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.

Maurice Sopacua (M)

MHeNs school for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands.

Auke B C Otten (ABC)

Department of Genetics and Cell Biology, Clinical Genomics Unit, Maastricht University, Maastricht, the Netherlands.

Monique M Gerrits (MM)

Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, the Netherlands.

Janneke G J Hoeijmakers (JGJ)

MHeNs school for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands.

Stephen G Waxman (SG)

Center for Neuroscience and Regeneration Research, VA Connecticut Healthcare System, West Haven, USA.

Raffaella Lombardi (R)

Neuroalgology Unit, IRCCS Fondazione Istituto Neurologico "Carlo Besta", Milan, Italy.

Giuseppe Lauria (G)

Neuroalgology Unit, IRCCS Fondazione Istituto Neurologico "Carlo Besta", Milan, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy.

Ingemar S J Merkies (ISJ)

Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Neurology, St. Elisabeth Hospital, Willemstad, Curaçao.

Hubert J M Smeets (HJM)

Department of Genetics and Cell Biology, Clinical Genomics Unit, Maastricht University, Maastricht, the Netherlands.

Catharina G Faber (CG)

MHeNs school for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands. Electronic address: c.faber@mumc.nl.

Jo M Vanoevelen (JM)

Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH